LMO2 Inhibitors
LIM domain only 2 (LMO2) is a transcriptional regulator involved in various cellular processes, including hematopoiesis, angiogenesis, and organ development. As a member of the LMO protein family, LMO2 contains LIM domains that mediate protein-protein interactions critical for its function. LMO2 acts as a transcriptional cofactor by forming complexes with other transcription factors, such as TAL1/SCL and GATA proteins, to modulate gene expression patterns essential for cell fate determination and differentiation. In hematopoietic cells, LMO2 plays a pivotal role in hematopoietic stem cell maintenance, as well as the development of various blood cell lineages, including erythrocytes, lymphocytes, and myeloid cells.
Inhibition of LMO2 activity can be achieved through several mechanisms, each targeting different aspects of its function. One approach involves disrupting protein-protein interactions between LMO2 and its transcriptional partners. By disrupting the formation of transcriptional complexes, inhibitors can interfere with the ability of LMO2 to regulate target gene expression, thereby attenuating its biological effects. Another strategy involves targeting post-translational modifications that modulate LMO2 activity. For instance, inhibitors may block the phosphorylation or acetylation of LMO2, leading to alterations in its stability, subcellular localization, or transcriptional activity. Additionally, inhibition of upstream signaling pathways that regulate LMO2 expression or activity can be effective in dampening its function. By targeting key signaling molecules or receptors involved in LMO2 activation, inhibitors can disrupt the cellular pathways necessary for its biological effects. Overall, inhibition of LMO2 offers a strategy for modulating cellular processes in which it plays a crucial role, providing insights into the development of interventions targeting LMO2-associated diseases.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $336.00 $1642.00 | 20 | |
Calphostin C is a potent inhibitor of protein kinase C (PKC). PKC is implicated in various signaling pathways, and its activation can lead to the modulation of downstream effectors. Calphostin C, by inhibiting PKC, interferes with the MAPK pathway. This interference disrupts the normal cascade of events, indirectly influencing LMO2, which is known to be regulated by MAPK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with activity against multiple targets, including Src family kinases. Src kinases are involved in various cellular processes, and their dysregulation can impact signaling pathways. Dasatinib's inhibition of Src kinases affects the JAK-STAT pathway, which has downstream effects on LMO2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of phosphoinositide 3-kinases (PI3Ks). The PI3K-AKT pathway is a critical signaling cascade involved in cell survival and proliferation. Wortmannin's inhibition of PI3K disrupts this pathway, impacting downstream molecules, including LMO2. The PI3K-AKT pathway is known to crosstalk with LMO2 signaling, and Wortmannin's action disrupts this crosstalk, indirectly modulating LMO2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cellular growth and proliferation. mTOR signaling intersects with various pathways, including those involving LMO2. Rapamycin's inhibition of mTOR disrupts the normal functioning of these pathways, indirectly influencing LMO2 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor targeting Raf kinases, among others. The Raf-MEK-ERK pathway is a central signaling cascade regulating cell growth and differentiation. Sorafenib's inhibition of Raf kinases disrupts this pathway, influencing downstream events, including those related to LMO2. The Raf-MEK-ERK pathway is known to interact with LMO2 signaling, and Sorafenib's interference alters the normal flow of information, indirectly modulating LMO2 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks). The PI3K-AKT pathway, regulated by PI3Ks, is crucial for cell survival and proliferation. LY294002's inhibition of PI3K disrupts this pathway, leading to downstream effects on LMO2. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 is a Janus kinase (JAK) inhibitor that interferes with JAK-STAT signaling. The JAK-STAT pathway is involved in diverse cellular processes, and its dysregulation can impact LMO2 signaling. Tyrphostin B42's inhibition of JAK disrupts this pathway, leading to downstream effects on LMO2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 mitogen-activated protein kinase (MAPK), a key player in stress response and inflammation. The p38 MAPK pathway intersects with various cellular processes, including those involving LMO2. SB203580's inhibition of p38 MAPK disrupts this pathway, influencing downstream events related to LMO2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), a member of the MAPK family. JNK signaling is involved in cellular responses to stress and inflammation. SP600125's inhibition of JNK disrupts this pathway, influencing downstream events related to LMO2. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e is a potent and selective inhibitor of histone deacetylase (HDAC) enzymes. HDACs play a role in chromatin remodeling and gene expression. VX-11e's inhibition of HDACs influences the epigenetic landscape, impacting the expression of various genes, including those related to LMO2. The modulation of HDAC activity by VX-11e showcases the role of epigenetic regulation in influencing LMO2 expression and function. | ||||||